KPV β Complete Research Guide (2026)
Last updated 2026-06-25
TL;DR
A tripeptide fragment of alpha-melanocyte-stimulating hormone studied for anti-inflammatory activity in preclinical models.
What is KPV?
KPV (lysine-proline-valine) is the C-terminal tripeptide fragment of the hormone alpha-melanocyte-stimulating hormone (alpha-MSH), studied for anti-inflammatory activity.
It is a research compound with no approval as a drug or dietary supplement by the FDA, EMA, or any other regulator, and is handled as research-use-only material.
The evidence base is almost entirely preclinical (cell culture and rodent colitis models); no controlled human efficacy trials have been published.
How does KPV work?
KPV appears to enter intestinal epithelial and immune cells partly via the peptide transporter PepT1 and to dampen pro-inflammatory NF-kappaB signaling.
As a fragment of alpha-MSH it retains part of the parent hormone's anti-inflammatory signature without full melanocortin-receptor pigmentary activity. [INFOGRAPHIC: KPV anti-inflammatory action via PepT1]
What does the research say about KPV?
- In rodent and cell-culture colitis models, KPV taken up via the PepT1 transporter reduces markers of intestinal inflammation. [1]
- Orally delivered KPV formulated in nanoparticles lessened the severity of experimentally induced ulcerative colitis in mice. [3]
- As the C-terminal fragment of alpha-MSH, KPV shows broad anti-inflammatory and protective activity across in-vitro and in-vivo models. [5]
Clinical research & studies
The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.
- [1] PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation β Dalmasso G et al., Gastroenterology 2008. (animal / in-vitro)
- [2] Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model β Viennois E et al., Cell Mol Gastroenterol Hepatol 2016. (animal)
- [3] Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis β Xiao B et al., Mol Ther 2017. (animal)
- [4] Self-Cross-Linked Hydrogel of Cysteamine-Grafted gamma-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats β Sun J et al., ACS Biomater Sci Eng 2021. (animal)
- [5] Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo β Brzoska T et al., Endocr Rev 2008. (review)
Dosing context
No validated human dose exists; published work uses cell-culture concentrations and rodent dosing that do not translate to human protocols.
Any figures circulated online are anecdotal and not supported by clinical dose-finding studies.
Side effects & safety profile
There are no controlled human safety trials of KPV; its safety profile in people is essentially uncharacterized.
Preclinical reports generally describe it as well tolerated at studied doses, but this does not establish human safety, purity, or long-term risk.
KPV is not an approved therapy and should be regarded strictly as a research chemical.
Stacking & combinations
There are no human data supporting combining KPV with other peptides or compounds, and such combinations remain unstudied research speculation.
Finding KPV vendors
Finding KPV vendors
This is an independent, neutral directory β we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.
Choose your country
We never list placeholder vendors. Pick your country to see neutral regulatory context.
User reviews
No reviews yet
Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews β we never fabricate ratings.
Frequently asked questions
No. KPV is not approved as a drug or supplement by the FDA, EMA, or other regulators. It is used only as a research compound.
References
- [1] PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation β Dalmasso G et al., Gastroenterology 2008. PMID: 18061177. View sourceStudy: animal / in-vitroKPV entered intestinal cells via the PepT1 transporter and reduced inflammatory responses in cell and mouse colitis models.
- [2] Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model β Viennois E et al., Cell Mol Gastroenterol Hepatol 2016. PMID: 27458604. View sourceStudy: animalPepT1-mediated delivery of KPV reduced inflammation and colitis-associated tumor development in mice.
- [3] Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis β Xiao B et al., Mol Ther 2017. PMID: 28143741. View sourceStudy: animalOrally administered KPV nanoparticles reduced ulcerative colitis severity in a mouse model.
- [4] Self-Cross-Linked Hydrogel of Cysteamine-Grafted gamma-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats β Sun J et al., ACS Biomater Sci Eng 2021. PMID: 34547895. View sourceStudy: animalA KPV-loaded hydrogel alleviated TNBS-induced ulcerative colitis in rats.
- [5] Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo β Brzoska T et al., Endocr Rev 2008. PMID: 18612139. View sourceStudy: reviewReviews evidence that alpha-MSH and its C-terminal tripeptides, including KPV, exert anti-inflammatory and tissue-protective effects.